Kartos Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
275 Shoreline Dr Ste 300, Redwood City, ...Phone Number
(650) 542-0130Website
www.kartosthera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Kartos Therapeutics
Kartos Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, targeted therapeutics to improve the lives of cancer patients. Their primary product is navtemadlin (KRT-232), an investigational MDM2 inhibitor designed to target the MDM2-p53 interaction, offering potential new treatment options for various solid tumors and hematological malignancies. The company is dedicated to advancing breakthrough therapies through active clinical studies. Their intended clients include patients suffering from cancer who may benefit from innovative treatment solutions.Explore more
Kartos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kartos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Kartos Therapeutics is spiking on competitors!
Product Launch: Get notified when Kartos Therapeutics launches new products
Kartos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Kartos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kartos Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Kartos Therapeutics recently announced quarterly report
Click to see if Kartos Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Kartos Therapeutics
Recommended Actions
Find VP level buyers at Kartos Therapeutics
Find 2 more new buyers
Compare Similar Companies to Kartos Therapeutics
Compare insights from companies similar to Kartos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kartos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kartos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kartos Therapeutics.
Kartos Therapeutics Tech Stack
A closer look at the technologies used by Kartos Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Facilities Relocation / Expansion
Kartos Therapeutics is planning to move offices in January 2026. The move will impact approximately 20 employees at the existing office located at 275 Shoreline Drive, Suite #300, Redwood City, CA.
Facilities Relocation/Expansion
New Hire
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Kartos Therapeutics News & Media
Kartos Therapeutics Appoints Dr. Srdan Verstovsek as Chief Medical Officer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer, today announced that Dr. Srdan (Serge) Verstovsek, MD, PhD, has been named Chief Medical Officer (CMO). Dr. Verstovsek is a world-renowned physician-scientist and a leading global authority on the treatment of myeloproliferative neoplasms (Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx test, which will be developed on Tempus’ xT platform, will be used to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible for treatmIllumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kartos Therapeutics
Sign Up For FreeTo access detailed company insights
Kartos Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, targeted therapeutics to improve the lives of cancer patients. Their primary product is navtemadlin (KRT-232), an investigational MDM2 inhibitor designed to target the MDM2-p53 interaction, offering potential new treatment options for various solid tumors... Read More
